Nom du produit:2-Chloro-5-nitronicotinic acid
IUPAC Name:2-chloro-5-nitropyridine-3-carboxylic acid
- CAS：42959-38-6
- Formule moléculaire：C6H3ClN2O4
- Pureté：95%+
- Numéro de catalogue：CM102625
- Poids moléculaire：202.55
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:42959-38-6
- Formule moléculaire:C6H3ClN2O4
- Point de fusion:-
- Code SMILES:O=C(O)C1=C(Cl)N=CC([N+]([O-])=O)=C1
- Densité:
- Numéro de catalogue:CM102625
- Poids moléculaire:202.55
- Point d'ébullition:384.8°C at 760 mmHg
- N° Mdl:MFCD06658402
- Stockage:Keep in inert atmosphere, store at room temperature.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- BNC-210
- Bionomics Ltd.’s drug candidate, BNC-210 would be advanced into Phase 3 studies in Social Anxiety Disorder (SAD) after the successful End-of-Phase 2 Meeting with the U.S. FDA in September. BNC-210 has a unique action potential that depends on acetylcholine neurotransmission and allosteric modulation of α7 nAChR. It is designed to treat patients with serious central nervous system (CNS) disorders with limited side effects. BNC-210 received Fast-Track designation from the FDA for the acute treatment of SAD.
Recherche 
+86 21 5895 0110 
